The risk of bone fracture increases after women stop a menopausic hormonal treatment

A new study revealed that women of protection against bone fracture obtain menopausic hormone therapy (MHT. Therefore, also known as HRT) disappears in the year following the stop of treatment.

In the new study. Nevertheless, published in Lancet healthy longevityExperts from the Medicine School of the University of Nottingham, also noted that in most cases, the cessation of treatment is then followed by a few years pupil Risk of fracture compared to women who have never used MHT. Therefore, The risk of fracture should then be similar, then lower than women who have never used MHT.

The study was funded by the National Institute for Health and Care Research (NIHR) SPCR.

During menopause, all women experience a drop in hormone levels, especially estrogens. Nevertheless, This can cause a range of painful mental risk bone fracture increases after and physical side effects, requiring the use of MHT. However, estrogen deficiency in women also increases age -related age bone. Meanwhile, Previous studies have confirmed a protective role of the estrogen component in MHT treatments. Moreover, and the MHT is known to reduce the risk of fracture when used.

However. For example, the MHT is also associated with an increased risk of breast cancer and blood clots, so that the use of long -term MHT is not recommended. For women using MHT to counter increasing bone fragility. it is therefore important to know the strength and persistence of any protective effect after stopping treatment. The detailed information on this aspect of previous studies has not been clear – covering only the first two years. and also being somewhat contradictory.

In this new study. experts used data for 6,000,000 women, from around 2,000 GP surgeries in the United Kingdom, allowing them risk bone fracture increases after to follow fracture risk levels up to 25 years. The researchers identified all women with first fracture recordings (case). each corresponded to a certain number of women of the same age and the same practice, but without fracture recording (witnesses). They then compared the use of the MHT in cases before their fracture with the use of the MHT. among their paired controls.

The results of our study confirmed that women under MHT show a risk of a fracture gradually reduced. compared to women not using MHT. More importantly, we also observed a clear risk change diagram after stopping treatment.

For most women. the bone protective effect of using the MHT disappears completely in approximately a year after stopping treatment, then their fracture risk increases compared to the users ever, culminating after about three years, before refusing to become equivalent to users ever – approximately 10 years after stopping risk bone fracture increases after – then continue to decline in relation to users. Thus. even after arresting the MHT, women should benefit from a risk of fracture in particular reduced in their last decades. “”

Dr. Yana Vinograva. from the Center for Academic Primary Care at the school of medicine, and the main author of the study

This observed risk scheme was the same for all menopausic hormonal treatments, but the level of excess risk depended on the type of treatment and the duration of the use of past MHT.

“Our comparative illustration of the observed models of risk of fracture with short. long use can help doctors and patients when they discuss the MHT treatment options, and to consider how the risk of fracture can change after stopping the use of the MHT. Increased risk periods may encourage doctors to check the bone health of patients with discontination. especially risk bone fracture increases after for patients most at risk with other fracture risk factors such as smoking or inactivity.

“These new results can also usefully stimulate new clinical and biological research on these treatments,” adds Dr Vinograva.